Novel targeted agents in the treatment of lung cancer

Bibliography

• JEMAL A, THOMAS A, MURRAY T et al.: Cancer statistics 2002. CA Cancer Clin. (2002) 52:23–47.
   PubMed Web of Science ®Google Scholar
• CARPENTER G, COHEN S: Epidermal growth factor. Annu. Rev. Biochem. (1979) 48:193–216.
   PubMed Web of Science ®Google Scholar
• YARDEN Y, ULLRICH A: Growth factor receptor tyrosine kinases. Annu. Rev Biochem. (1988) 57:443–478.
   PubMed Web of Science ®Google Scholar
• CARPENTER G, COHEN S: Epidermal growth factor. Biol. Chem. (1990) 265:7709–7712.
   Web of Science ®Google Scholar
• GULLICK WJ: Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br. Med. Bull. (1991) 47:87–91.
   PubMed Web of Science ®Google Scholar
• YARDEN Y, SLIWKOWSKI M: Untangling the ErbB signaling network. Nat. Rev MM. Cell. Biol. (2001) 2:127–137.
   PubMed Web of Science ®Google Scholar
• ALROY I, YARDEN Y: The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinational ligand-receptor interactions. FEBS Lett. (1997) 410:83–86.
   PubMed Web of Science ®Google Scholar
• LEWIS TS, SHAPIRO PS, AHN NG: Signal transduction through MAPkinase cascades. Adv. Cancer Res. (1998) 74:49–139.
   PubMed Web of Science ®Google Scholar
• CARTER AS, AUER KL, REARDON DB:Inhibition of the mitogen activated protein (MAP) kinase cascade potentiates cell killing by low-dose ionizing radiation in A431 human squamous cell carcinoma cells. Oncogene (1998) 16:2787–2796.
   PubMed Web of Science ®Google Scholar
• VIVANCO I, SAWYERS CL: The phosphatidylinositol 3-kinase-Akt pathway in human cancer. Nat. Rev Cancer (2002) 2:489–501.
   PubMed Web of Science ®Google Scholar
• GRANA TM, RUSYN EV, ZHOU H EA: Ras mediates radioresistance through both phosphatidylinositol 3-kinase dependent and Raf-dependent but mitogen-activated protein kinase/exctracellular signal regulated kinase kinase-independant signaling pathways. Cancer Res. (2002) 62:4142–4145.
   PubMed Web of Science ®Google Scholar
• JIANG K, COPPOLA D, CRESPO NC et al.: The phosphoinositide 3-0H kinase/ AKT2 pathway as a critical target for farnesyl-transferase inhibitor-induced apoptosis. Ma Cell. Biol. (2000) 20:139–148.
   Web of Science ®Google Scholar
• RUBIN GRANDIS RJ, CHAKRABORTY A, MELHEM MF: Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. Oncogene (1997) 15:409–416.
   PubMed Web of Science ®Google Scholar
• GRANDIS JR, MELHEM MF, BARNES EL: Quantitative immunohistochemical analysis of transforming growth factor-a and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer (1996) 78:1284–1292.
   PubMed Web of Science ®Google Scholar
• LIU D, GHISO JA, ESTRADA Y et aL: EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell (2002) 1:445–457.
   PubMed Web of Science ®Google Scholar
• PFEIL K, EDER IE, PUTZ T et al: Long-term androgen ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells. Prostate (2004) 15:259–268.
   Google Scholar
• ZHANG J, CHOI Y, MAVROMATIS B et al.: Preferential killing of PTEN-null myelomas by PI3K inhibitors through Aid pathway. Oncogene (2003) 18:6289–6295.
   Google Scholar
• SHE QB, SOLIT D, BASSO A et al: Resistance to Gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3-kinase/Akt pathway signaling. Clin. Cancer Res. (2003) 1:4340–4346.
   Google Scholar
• ALLEN LF, LENCHAN PF, EISMAN IA et al.: Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer. &min. Oncol June (2002) 29:11–21.
   Google Scholar
• SLICHENMYER WJ, ELLIOTT WL, FRY DW: CI-1033, a pan-erbB tyrosine kinase inhibitor. Seinin. Oncol (2001) 28:80–85.
   PubMed Web of Science ®Google Scholar
• GIACCONE G, JOHNSON DH, MANE GOLD C: A Phase III clinical trial of ZD 1839 (Iressa) in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-small cell lung cancer (INTACT1). Ann. Oncol (2002) 13:2.
   Google Scholar
• ••Gemcitabine and cisplatinurn withgefitinib or placebo followed by maintenance gefitinib or placebo did not produce an improved efficacy or a survival benefit of patients on gefitinib.
   Google Scholar
• JOHNSON D, HERBST R, GIACONNE G: ZD1839 (Iressa) in combination with paclitaxel and carboplatin in chemotherapy-naive patients with advanced non-small cell lung cancer: results from a phase II clinical trial (INTACT2). Ann. Oncol (2002) 13:2.
   Google Scholar
• ••Combination of paclitaxel and carboplatinwith or without gefitinib failed to produce any advantages including survival advantages for patients on the gefitinib arm in this randomised, double-blind Phase II trial.
   Google Scholar
• SIROTNAK F, ZAKOWINSKI M, MILLER V et al.: Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD 1839 (IRESSA), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. (2000) 6:4885–4892.
   PubMed Web of Science ®Google Scholar
• WAKELING AE, GUY SP, WOODBURN JR et al: ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. Oct (2002) 15:5749–5754.
   Google Scholar
• RUSCH V, BASELGA J, CORDON-CARDO C et al: Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res. (1993) 53:2379–2385.
   PubMed Web of Science ®Google Scholar
• RUSCH V, KLIMSTRA D, VENKATRAMAN E et al: Overexpression of epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin. Cancer Res. (1997) 3:515–522.
   PubMed Web of Science ®Google Scholar
• MENDELSOHN J: Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clinical Cancer Res. (1997) 3:2703–2707.
   PubMed Web of Science ®Google Scholar
• MILLER VA, JOHNSON DH, HEELAN RT et al: A pilot trial demonstrates the safety of ZD 1839 (Iressa, an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with carboplatin (c) and paclitaxel (p) in previously untreated advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol (2001) 20:326a.
   Google Scholar
• CAMPIGLIO M, LOCATELLI A, OLGIATI C et al.: Inhibition of proliferation and induction of apoptosis in breast cancer cells by epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (Iressa) is independant of EGFR expression level. j. Cell. Physiol (2004) 198(2):259–268.
   PubMed Web of Science ®Google Scholar
• HIDALGO M: Erlotinib: preclinical investigations. Oncology (2003) 17(11 Suppl. 12):11–16.
   Google Scholar
• GRUNWALD V, HIDALGO M: Development of the epidermal growth factor receptor inhibitor Tarceva (OSI-774). Adv. Exp. Biol. (2003) 532:235–246.
   PubMed Web of Science ®Google Scholar
• GATZEMEIER U: Targeting the HER1/EGFR receptor to improve outcomes in non-small cell lung cancer. Oncology(2003) 17(11 Suppl. 12):7–10.
   Google Scholar
• GILL GN, KAWAMOTO T, COCHET C: Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor bindingand antagonists of the epidermal growth factor stimulated tyrosine protein kinase activity. Biol. Chem. (1984) 259:7755–7760.
   Web of Science ®Google Scholar
• SATO JD, KAWAMOTO T, LE AD et al:Biological effects M vitro of monoclonal 623 antibodies to human EGF receptors. MM. Biol. Med (1983) 1:511–529.
   Google Scholar
• SARUP JC, JOHNSON PM, KING KL et al.: Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. Growth Regal. (1991) 1:72–82.
   PubMedGoogle Scholar
• MASUI H, KAWAMOTO T, SATO JD et al.: Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. (1984) 44:1002–1007.
   PubMed Web of Science ®Google Scholar
• PARK JW, STAGG R, LEWIS G.D et al.:Anti-p185HER2 monoclonal antibodies: biological properties and potential for immunotherapy. In: Genes Oncogenes, and Hormones. Advances in Cellular, and Molecular Biology of Breast Cancer. RB Dickson and ME Lippman (Eds), Kluiwer Academic Publishers, Boston, USA (1991).
   Google Scholar
• SOLOMON DS, BRANDT R, CIARDIELLO F: Epidermal growth factor related peptides and their receptors in human malignancies. Crit. Rev Oncol Hematol. (1995) 19:183–232.
   PubMed Web of Science ®Google Scholar
• SHIN DM, DONATO NJ, PEREZ-SOLER R et al.: Epidermal growth factor receptor-targeted with C225 and Cisplatin in patients with head and neck cancer. Clin. Cancer Res. (2001) 7(5):1204–1213.
   PubMed Web of Science ®Google Scholar
• •EGFR-targeted therapy with C225 (a human mouse chimerised mAb) shows binding and saturation of C225 on the EGFR and provides a novel mechanism for targeting cancer therapy in patients whose tumours express EGFR.
   Google Scholar
• WU X, FAN Z, MASUI H: Apoptosis induced by an epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J. Clin. Invest. (1995) 95:1897–1905.
   PubMed Web of Science ®Google Scholar
• BRUNS CJ, HARBISON MT, DAVIS SW: Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin. Cancer Res. (2000) 6:1936–1948.
   PubMed Web of Science ®Google Scholar
• PREWETT M, ROCKWELL P, ROCKWELL RF: The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. Immunother. Emphasis Tumor Immunol. (1996) 19:419–427.
   PubMed Web of Science ®Google Scholar
• MOYER JD, BARBACCI EG, IWATA KK: Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. (1997) 57:4838–4848.
   PubMed Web of Science ®Google Scholar
• BASELGA J, NORTON L, MASUI H: The antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. Nati Cancer Inst.(1993) 85.
   Google Scholar
• HERBST RS, LANGER CJ: Epidermal growth factor receptors as a target for cancer treatment: The emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin. Oncol (2002) 29:27–36.
   PubMed Web of Science ®Google Scholar
• KIM ES, MAUER AM, FOSSELLA FV: A phase II study of erbitux (IMC-C225), an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/ resistant patients with advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Oncol (2002) 21.
   Google Scholar
• FOON KA, YANG XD, WEINER LM et al.: Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int. Oncol Biol. Phys. Mar (2004) 1:58(3):984–990.
   Google Scholar
• YANG XD, JIA XC, CORVALAN JR et al: Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Grit. Rev Oncol Hematol (2001) 38(1):17–23.
   PubMed Web of Science ®Google Scholar
• RANSON M: Technology evaluation: ABX-EGF, Abgenix/Amgen. Carr. Opin. Mol .Ther: (2003) 5(5):541–546.
   PubMed Web of Science ®Google Scholar
• TATEISHI M, ISHIDA T, MITSUDOMI T: Prognostic value of C-ErbB2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. Ear. Cancer (1991) 27:1372–1375.
   PubMed Web of Science ®Google Scholar
• KERN JA, SCHWARTZ DA, NORDBERG JE: P185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res. (1990) 50:5184–5187.
   PubMed Web of Science ®Google Scholar
• GATZMEIER U, GROTH G, BRITTS C et al.: Randomized phase II trial of Gemcitabine-Cisplatin with or without transtuzumab in Her-2 positive non-small cell lung cancer. Ann. Oncol (2004) 15:19–27.
   PubMed Web of Science ®Google Scholar
• HIRSCH FR, LANGER CJ: The role of Her2/neu expression and Transtuzumab in non-small cell lung cancer. &min. Oncol (2004) 31:75–82.
   Google Scholar
• KHURI FR, RIGAS JR, FIGLIN RA et al.: Multi-institutional phase I/II trial of oral bexarotene in combination with cisplayin and vinorelbine in previously untreated patients with advanced non-small cell lung cancer.j Clin. Oncol May(2001) 15:2626–2637.
   Google Scholar
• •A Phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with NSCLC yielded a Phase II response rate of 25% and a prolonged survival of 14 months.
   Google Scholar
• NGUYEN TT, TRAN E, ONG CK et al.:Kaempferol induced growth inhibition and apoptosis in A549 lung cancer cells is mediated by activation of MEK-MAPK. Cell. Physiol (2003) 197(1):110–121.
   Web of Science ®Google Scholar
• TAXMAN DJ, MACKEIGAN JP, CLEMENTS C et al.: Transcriptional profiling of targets for combination therapy of lung carcinoma with paclitaxel and mitogen-activated protein/extracellular signal regulated kinase kinase inhibitor. Cancer Res. (2003) 15:5095–5104.
   Google Scholar
• DUBOIS RN, ABRAMSON SB, CROFFORD L: Cyclooxygenase in biology and disease. FASEB (1998) 12:1063–1073.
   PubMed Web of Science ®Google Scholar
• HERSCHMAN HR, XIE W, REDDY S: Inflammation, reproduction, cancer and all that .The regulation and role of the inducible prostaglandin synthase. Bioassays (1995) 17:1031–1037.
   Google Scholar
• EBERHART CE, COFFEY RJ, RADHIKA A: Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastrenterology (1994) 107:1183–1188.
   PubMed Web of Science ®Google Scholar
• WADDELL WR, LOUGHRY RW: Sulindac for polyposis of the colon." Surg. Oncol (1983) 24:83–87.
   PubMed Web of Science ®Google Scholar
• THUN MJ, NAMBOODIRI MM, HEATH CW JR: Aspirin use and reduced risk of fatal colon cancer. N Engl. Med. (1991) 325:1593–1596.
   PubMed Web of Science ®Google Scholar
• STAEINBACH G, LYNCH PM, PHILLIPS RK: The effect of celecmdb, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl. I Med. (2000) 342:1946–19452.
   PubMed Web of Science ®Google Scholar
• TSOUBOUCHI Y, MUKAI S, KAWAHITO Y et al: Meloxicam inhibits 624 the growth of non-small cell lung cancer. Anticancer Res. (2000) 20:2867–2872.
   PubMed Web of Science ®Google Scholar
• MASFERRERJL, LEAHY KM, KOKI AT: Antiangiogenic and anti-tumor activities of cyclooxygenase-2 inhibitors. Cancer Res. (2000) 60:1306–1311.
   PubMed Web of Science ®Google Scholar
• JOKI T, HEESE 0, NIKAS DC: Expression of cyclooxygenase 2 (COX-2) in human glioma and in-vitro inhibition by a specific COX-2 inhibitor, NS-398. Cancer Res. (2000) 60:127–131.
   Google Scholar
• ROZIC JG, CHAKRABORTY C, LALA PK: Cycoloxygenase inhibitors retarded human mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis. hat. Cancer (2001) 93:497–506.
   Web of Science ®Google Scholar
• KANG J, KIM E, SHIN H et al.: The overexpression of cyclooxygenase - 2 (COX-2) and antitumor effect of selective COX-2 inhibitor (SC-236) in gastric cancer. Proc. Am. Soc. Clin. Oncol (2000) 19 (Abstract 1279).
   Google Scholar
• DING XZ, TONG WG, ADRIAN TE: BLockade of cyclooxygenase-2 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Anticancer Res. (2000) 20:2625–2632.
   PubMed Web of Science ®Google Scholar
• LIU XH, KIRSCHENBAUM A, YAO S et al.: Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. Urol. (2000) 164:820–825.
   Web of Science ®Google Scholar
• LIAO Z, KOMAKI R, MASON KA et al:Role of cyclooxygenase-2 inhibitors in combination with radiation therapy in lung cancer. Clin. Lung Cancer (2003) 4:356–365.
   PubMedGoogle Scholar
• PYO H, CHOY H, AMORINO GP: A selective cyclooxygenaase-2 inhibitor, NS-398, enhances the effect of radiation in-vitro and in-vivo preferentially on the cells that express cyclooxygenase-2. Clin. Cancer Res. (2001) 7:2998–3005.
   PubMed Web of Science ®Google Scholar
• KRYSAN K, MERCHANT FH, ZHU L et al.: COX-2 dependant stabilization of survivin in non-small cell lung cancer. FASEB J. (2204) 18(1):206–208.
   Google Scholar
• KIM HS, YOUM HR, LEE JS et al.: Correlation betwen cyclooxygenase-2 and tumor angiogenesis in non-small cell lung cancer. Lung Cancer (2003) 42:163–170.
   PubMed Web of Science ®Google Scholar
• SAHA D, CHOY H: Potential for combined modality therapy of cyclooxygenase inhibitors and radiation. Frog. Exp. Tumor Res. (2003) 37:193–209.
   PubMed Web of Science ®Google Scholar
• NAKATA H, UEMURA Y, KOBAYASHI M et al.: Cyclooxygenase-2 inhibitor NS-398 suppresses cell growth and constitutive production of granulocyte colony stimulating factor and granulocyte macrophage colony stimulating factor in lung cancer cells. Cancer Sci. (2003) 94:173–180.
   PubMed Web of Science ®Google Scholar
• SANCHEZ-ALCAZAR JA, BRADBURY DA, PANG L et al.: Cyclooxygenase (COX) inhibitors induce apoptosis in non-small cell lung cancer through cyclooxygenase independant pathways. Lung Cancer (2003) 40:33–44.
   PubMed Web of Science ®Google Scholar
• TIAN F, WANG TY, GONG M et al: Overexpression of COX-2 and its clinical significance in non-small cell lung cancer. Zhonghua Wai Ke Za Zhi (2003) 41:407–410.
   PubMedGoogle Scholar
• KHURI FR, WU H, LEE JJ et al.: Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin. Cancer Res. (2001) 7(4):861–867.
   PubMed Web of Science ®Google Scholar
• •Expression of COX-2 in NSCLC tissue correlates with shorter survival among patients with early stage NSCLC and correlates with RAR-I3 expression.
   Google Scholar
• FANG HY, LIN TS, LIN JP et al: Cyclooxygenase-2 in human non-small cell lung cancer. Eur: Surg. Oncol (2003) 29:171-177. ao. ALTORKI NK, KERESZTES RS, PORT JL et al.: Celecoxib a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small cell lung cancer.' Clin. Oncol (2003) 21:2631–2632.
   Google Scholar
• •Patients with NSCLC preoperatively treated with celecoxib (a COX-2 inhibitor) and combination chemotherapy, in a Phase II trial, had an overall response of 65%, and was correlated with abrogation of the PGE2 levels in the primary tumour.
   Google Scholar
• ZOHN IM, CAMPBELL SL, KHOSRAVI-FAR R: Rho family proteins and Ras transformation: The RHOad less traveled gets congested. Oncogene (1998) 17:1415–1438.
   PubMed Web of Science ®Google Scholar
• BOS JL: ras oncogenes in human cancer: a review. Cancer Res. (1989) 49:4682–4689.
   PubMed Web of Science ®Google Scholar
• BOLLAG G, MeCORMICK F: Regulators and effectors of Ras proteins. Annu. Rev Cell Biol. (1991) 7:601–632.
   PubMedGoogle Scholar
• ROSELL R, LI S, SKACEL Z: Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients. Oncogene (1993) 8:2407–2412.
   PubMed Web of Science ®Google Scholar
• SLEBOS RJ, KIBBELAAR RE, DALESIO 0: K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl. I Med. (1990) 323:561–565.
   PubMed Web of Science ®Google Scholar
• LERNER EC, QUIAN Y, HAMILTON AD: Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor. Biol. Chem. (1995) 270:26770–26773.
   Web of Science ®Google Scholar
• LERNER EC, ZHANG TT, KNOWLES DB: Inhibition of the phenylation of K-ras, but not H- or N-ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyl-transferase and a geranylgeranyltransferaseI inhibitor in human tumor cell lines. Oncogene (1997) 15:1283–1288.
   PubMed Web of Science ®Google Scholar
• BARBACID M: ras genes. Annu. Rev Biochem. (1987) 56:779–827.
   PubMed Web of Science ®Google Scholar
• LIU M, BTYANT MS, CHEN J: Antitumor activity of 5CH66336, an orally bioavailable tryciclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res. (1998) 58:4947–4956.
   PubMed Web of Science ®Google Scholar
• ADJEI AA, DAVIS JN, BRUZEK LM et al.: Synergy of the protein farnesyltransferase inhibitor 5CH66336 and cisplatin in human cancer cell lines. Gin. Cancer Res. (2001) 7:1438–1445.
   Web of Science ®Google Scholar
• SHI B, YAREMKO B, HAJIAN G: The farnesyl protein transferase inhibitor 5CH66336 synergises with taxanes in vitro and enhances their antitumor activity in vivo. Cancer Chemother: Pharmacol (2000) 46:387–393.
   PubMed Web of Science ®Google Scholar
• KIES MS, CLAYMAN GL, EL-NAGGAR AK: Induction therapy with 5CH66336, a farnesyltransferase inhibitor, in squamous cell carcinoma (SCC) of the head and neck. Proc. Am. Soc. Gin. Oncol (2001) 20:225a (Abstract 896).
   Google Scholar
• ADJEI AA, ERLICHMAN C, DAVIS JN:A Phase I trial of farnesyltransferase inhibitor 5CH66336: evidence of biological and clinical activity. Cancer Res. (2000) 60:1871–1877.
   PubMed Web of Science ®Google Scholar
• KHURI FR, GLISSON BS, KIM ES et al.:Phase I study of farnesyltransferase inhibitor (FTI) lonafarnib with paclitaxel in solid tumors. Clin. Cancer Res. (2004) 10:2968–2976.
   PubMed Web of Science ®Google Scholar
• •A Phase I study of lonafarnib and paclitaxel given every 3 weeks to patients with solid tumours, including NSCLC, produced a durable response in 8 of 21 evaluable patients.
   Google Scholar
• KHURI FR, GLISSON BS, KIM ES et al: Phase I study of farnesyltransferase inhibitor (FTI) lonafarnib with paclitaxel in solid tumors. (Manuscript submitted for publication).
   Google Scholar
• •Patients with stage IIIB or IV NSCLC progressing while on taxane-based therapy received continuous oral lonafarnib. Among 29 evaluable patients 3 had a partial response and 11 had stabilisation of disease.
   Google Scholar
• KIM ES, KIES MS, FOSSELLA FV et al.:Phase II study of farnesyltransferase inhibitor (FTI) lonafarnib with paclitaxel in patients with taxane-refractory/resistant non-small cell lung cancer. (Manuscript submitted for publication).
   Google Scholar
• ROWINSKI EK, WINDLE JJ, VON HOFF DD: Ras protein farnesyl-transferase: a strategic target for anti-cancer therapeutic development. Clin. Oncol. (1999) 17:3631–3652.
   Web of Science ®Google Scholar
• END DW, SMETS G, TODD AV: Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res. (2001) 61:131–137.
   PubMed Web of Science ®Google Scholar
• CRUL M, DE KLERK GJ, SWART M: Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. Clin. Oncol. (2002) 20:2726–2735.
   Web of Science ®Google Scholar
• PATNAIK A, ECKHARDT SG, IZBICKA E et al.: A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies. Clin. Cancer Res. Oct (2003) 15:4761–4771.
   Google Scholar
• JOHNSTON SR, HICKISH T, ELLIS P et al.: Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyltransferase inhibitor, R115777, in advanced breast cancer. J. Clin. Oncol. (2003) 21:2492–2499.
   PubMed Web of Science ®Google Scholar
• ADJEI AA, MAUER A, BRUZEK L et al: Phase II study of Farnesyl transferase inhibitor RU 5777 in patients with advanced non-small cell lung cancer. .1 Clin. Oncol. (2003) 21:1760–1766.
   PubMed Web of Science ®Google Scholar
• SUN J, BLASKOVICH MA, KNOWLES D: Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase I: combination therapy with the cytotoxic agents cisplatin, taxol, and gemcitabine. Cancer Res. (1999) 59:4919–4926.
   PubMed Web of Science ®Google Scholar
• MOASSEER MM, SEPP-LORENZINO L, KOHL NE: Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc. Nati Acad. Sci USA (1998) 95:1369–1374.
   PubMed Web of Science ®Google Scholar
• FOLKMAN J: Seminars in medicine of the Beth Israel Hospital, Boston: Clinical applications of research on angiogenesis. N. Engl. Med. (1995) 333:1757–1763.
   PubMed Web of Science ®Google Scholar
• FOX SB, GASPARINI G, HARRIS AL: Angiogenesis: Pathological, prognostic, and growth factor pathways and their link to trial design and anti-cancer drugs. Lancet Oncol. (2001) 2:278–289.
   PubMed Web of Science ®Google Scholar
• KERBAL RS: Clinical trials in anti-angiogenic drugs: opportunities, problems, and assessment of initial results. Clin. Oncol. (2001) 19.
   Google Scholar
• COX G, WALKER RA, ANDI A et al: Prognostic significance of platelet and microvessel counts in operable non-small cell lung cancer. Lung Cancer (2000) 29:169–177.
   PubMed Web of Science ®Google Scholar
• GIATROMANOLAKI A, KOUKOURAKIS MI, KAKOLYRIS S: Vascular endothelial growth factor, wild-type P53 and angiogenesis in early operable non-small cell lung cancer. Clin. Cancer Res. (1998) 4:3017–3024.
   PubMed Web of Science ®Google Scholar
• GIATROMANOLAKI A, KOUKOURAKIS MI, COMLEY M: Platelet derived endothelial cell growth factor (thymidine phosphorylase) expression in lung cancer. Pathol. (1997) 181:196–199.
   Web of Science ®Google Scholar
• GIATROMANOLAKI A, KOUKOURAKIS M, O'BYRNE K: Prognostic value of angiogenesis in operable non-small cell lung cancer. Pathol. (1996) 179:80–88.
   Web of Science ®Google Scholar
• FONTANINI G, VIGNATI S, BOLDRINI L: Vascular endothelial growth factor is associated with neovascularization and influencesprogression of non-small cell lung carcinoma. Clin. Cancer Res. (1997) 3:861–865.
   PubMed Web of Science ®Google Scholar
• FONTANINI G, LUCCHI M, VIGNATI S: Angiogenesis as a prognostic indicator of survival in non-small cell lung carcinoma: A prospective study. Natl. Cancer Inst. (1997) 89:881–886.
   Google Scholar
• HIDALGO M, ECKHARDT SG: Development of matrix metalloproteinase inhibitors in cancer therapy. Natl. Cancer Inst. (2001) 93:178–193.
   Google Scholar
• OZDEMIR E, KAKEHI Y, OKUNO H: Role of matrix metalloproteinase-9 in the basement membrane destruction of superficial urothelial carcinomas. Urol. (1999) 161:1359–1363.
   Web of Science ®Google Scholar
• SHOU Y, HIRANO T, GONG Y: Influence of angiogenic factors and matrix metalloproteinases upon tumor progression in non-small cell lung cancer. Br. Cancer (2001) 85:1706–1712.
   Google Scholar
• KARAMERIS M, PANAGOU P, TSILALIS T: Association of expression of metalloproteinases and their inhibitors with the metastatic potential of squamous-cell lung carcinoma. Arn J Rasp Grit. Care Med. (1997) 156:1930–1936.
   PubMed Web of Science ®Google Scholar
• KHOKHA R, BENHARDT DT: Matrix metalloproteinases and tissue inhibitor of metalloproteinases: a review of their role in tumorigenesis and tissue invasion. Invasion Metastasis (1989) 9:391–405.
   PubMedGoogle Scholar
• FORTUNATO SJ, MENON R: Screening for novel matrix metalloproteinases in human fetal membranes. Assist. Reprod. Genet. (2002) 19:483–486.
   PubMed Web of Science ®Google Scholar
• MICHAEL M, BABIC B, KHOKHA R: Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer. Clin. Oncol. (1999) 17:1802–1808.
   Web of Science ®Google Scholar
• WOJTOWICZ-PRAGA SM, DICKSON RB, HAWKINS MJ: Matrix metalloproteinase inhibitors. Invest. New Drugs (1997) 15:61–75.
   PubMed Web of Science ®Google Scholar
• SHEPHERD FA, GIACCONE G, SEYMOUR L: Prospective, randomized, double blind, placebo-controlled trial of marismatat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-clinical Trials Group and the European Organization for Research and Treatment of Cancer. Clin. Omni (2002) 20:4434–4439.
   PubMed Web of Science ®Google Scholar
• FALARDEAU P, CHAMPAGNE P, POYET P, HARITON C, DUPONT E: Novastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Sernin. Oncol. (2001) 28:620–625.
   PubMed Web of Science ®Google Scholar
• LIU J, TSAO MS, PAGURA M et al.: Early combination treatment with carboplatin and the MMP inhibitor, prinomastat, prolongs survival and reduces systemic metastasis in an aggressive orthotopic lung cancer model. Lung Cancer (2003) 42:335–344.
   PubMed Web of Science ®Google Scholar
• BEHRENDT CE, RUIZ RB: Venous thromboembolism among patients with advanced lung cancer randomized to prinomastat or placebo, plus chemotherapy. Thromb. Haemost. (2003) 90(4)734–737.
   Google Scholar
• BRAMHALL SR, HALLISSEY MT, WHITING J et al: Marismatat as maintenance therapy for patients with advanced gastric cancer: a randomized trial. Br.Cancer June (2002) 17:1864–1870.
   Google Scholar
• •A randomised trial of marismatat (a MMP inhibitor) demonstrated a survival advantage in patients with advanced gastric cancer.
   Google Scholar
• HEATH El, O'REILLY S, HUMPHREY R et al.: Phase I trial of matrix metalloproteinase inhibitor BAY-12-9566 in patients with advanced solid tumors. Cancer Chemother. Pharmacol (2001) 48(4):269–274.
   Google Scholar
• ERLICHMAN C, ADJEI AA, ALBERTS SR et al.: Phase I study of the matris metalloproteinase inhibitor, BAY12-9566. Ann. Oncol (2001) 12:389–395.
   PubMed Web of Science ®Google Scholar
• RUDEK MA, VENITZ J, ANDO Y et al.: Factors involved in the pharmacokinetics of Col-3, a matrix metalloproteinase inhibitor, in patients with refractory, metastatic cancer. Clin. Pharmacol (2003) 43(10):1124–1135.
   Google Scholar
• FERRARA N: Molecular and biological properties of vascular endothelial growth factor. J. Ma Med. (1999) 77:527–543.
   PubMed Web of Science ®Google Scholar
• DE VORE RF, FEHRENBACHER RS, HERBST RS: A randomized phase III trial comparing rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage III/IV NSCLC. Proc. Am. Soc. Clin. Oncol (2000) 19:485a (Abstract 1896).
   Google Scholar
• LANGMUIR VK, COBLEIGH MA, HERBST RS et al.: Successful long-term therapy with bevacizumab (Avastin) in solid tumors. Proceedings ASCO (2002) 21:Abstract 32.
   Google Scholar
• KABBINAVAR F, HURWITZ HI, FECHRENBACHER L et al.: Phase II randomized trial comparing bevacizumab plus fluorouracil (FU)/Leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. I. Clin. Oncol (2003) 1:60–65.
   Google Scholar
• BRUNS CJ, SHRADER M, HARBISON MT et al.: Effect of vascular endothelial growth factor receptor-2 antibody DC101 plus gencitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mince. Int. J. Cancer (2002) 102:101–108.
   PubMed Web of Science ®Google Scholar
• FONG TA, SHAWVER LK, SUN L: 5U5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. (1999) 59:99–106.
   PubMed Web of Science ®Google Scholar
• SHAHEEN RM, DAVIS DW, LIU W: Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res. (1999) 59:5412–5416.
   PubMed Web of Science ®Google Scholar
• ROSEN L, MULAY M, MAYERS A: Phase I dose escalating trial of 5U5416, a novel angiogenesis inhibitor in patients with advanced malignancies. Proc. Am. Soc. Clin. Oncol (1999) 18:161a (Abstract 618).
   Google Scholar
• ROSEN PJ, AMADO R, HECHT JR: A phase I/II study of 5U5416 in combination with 5FU/leucovorin in patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol (2000) 19:3a (Abstract 5D).
   Google Scholar
• HURWITZ H, HOLDEN SN, ECKHARDT SG: Clinical evaluation of ZD6474, an orally active inhibitor of VEGF signaling in patients with solid tumors. Proc. Am. Soc. Clin. Oncol (2000) 21:82a (Abstract 325).
   Google Scholar
• O'REILLY MS, BOEHM T, SHING Y: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastasis by a Lewis lung carcinoma. Cell (1994) 79:315–328.
   PubMed Web of Science ®Google Scholar
• SUGARBAKER E, THORN WAIT J, KETCHAM A: Inhibitory effect of a primary tumor on metastasis. In: Progress in Cancer Research and Therapy S Day, P Myers (Eds), Raven Press, New York, USA (1977):227–240.
   Google Scholar
• SIM BK, O'REILLY MS, LIANG H: A recombinant human angiostatin inhibits experimental primary and metastatic cancer. Cancer Res. (1997) 57:1329–1334.
   PubMed Web of Science ®Google Scholar
• MAUCERI HJ, HANNA N, BECKETT MA: Combined effects of angiostatin and ionizing radiation in antitumor therapy. Nature (1998) 394:287–291.
   PubMed Web of Science ®Google Scholar
• O'REILLY MS, BOEHM T, SHING Y: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell(1997) 88:277–285.
   PubMed Web of Science ®Google Scholar
• BOEHM T, FOLKMAN J, SHING Y: Antiangiogenic therapy of experimental cancer does not induce aquired drug resistance. Nature (1997) 390:404–407.
   PubMed Web of Science ®Google Scholar
• BLACK WR, AGNER RC: Tumor regression after endostatin therapy. Nature (1998) 391:450.
   PubMed Web of Science ®Google Scholar
• HERBST RS, HESS KR, IRAN HT: Phase I study of recombinant human endostatin in patients with advanced solid tumors. Clin. Omni (2002) 20:3792–3803.
   PubMed Web of Science ®Google Scholar
• •A Phase I study of recombinant endostatin in patients with advanced solid tumours was well-tolerated and revealed evidence of antiturnour activity.
   Google Scholar
• HERBST RS, MADDEN TL, IRAN HT et al.: Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small cell lung cancer. I Clin. Omni (2002) 20(22)4440–4447.
   Google Scholar
• YAMAGUCHI M, SUGIO K, ONDO K et al.: Reduced expression of thrombospondin-1 correlates with poor prognosis in patients with non-small cell lung cancer. Lung Cancer (2002) 36(2):143–150.
   PubMed Web of Science ®Google Scholar
• REIHER FK, VOLPERT OV, JIMENEZ B et al.: Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics. In. Cancer (2002) 98(5):682–689.
   Web of Science ®Google Scholar
• VICACQUA RJ, LEBEDDA J, WA K: Phase I/II study of sequential interferon-a-2b (IFN-a-2b) and weekly topotecan/vinorelbine in advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol (2002) 226 (Abstract 2721).
   Google Scholar
• LIU CW, CORBOY MJ, DEMARTINO GM et al: Endoproteolytic activity of the proteasome. Science (2003) 299:408–411.
   PubMed Web of Science ®Google Scholar
• ADAMS J, PALOMBELLA VJ, EA S: Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. (1999) 59:139–145.
   Google Scholar
• CATZAVELOS C, TSAO MS, DEBOER G et al.: reduced expression of the cell cycle inhibitor p27kipl in non-small cell lung carcinoma: a prognostic factor independant of Ras. Cancer Res. (1999) 59:684–688.
   PubMed Web of Science ®Google Scholar
• LI B, QP D: Bax degradation by the ubiquitin/proteasome-dependant pathway: involvement in tumor survival and progression. Proc. Nati Acad. Sri. USA (2000) 97:3850–3855.
   PubMed Web of Science ®Google Scholar
• SUNWOO JB, CHEN Z et al.: Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-KB, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin. Cancer Res. (2001) 7:1419–1428.
   PubMed Web of Science ®Google Scholar
• RYAN DP, EDER JP et at: Pharmacokinetic and pharmacodynamic phase I study of PS-341 and Gemcitabine in patients with advanced solid tumors. Proc Am Soc Clin Oncol. (2002)
   Google Scholar
• CUZAC JC, LIU R, et al: Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implication for systemic nuclear factor kappaB inhibition. Cancer Res. (2001) 61:3535–3540.
   PubMed Web of Science ®Google Scholar
• TEICHER BA, ARA G, HERBST R et al.: The poteasome inhibitor PS-341 in cancer therapy. Clin. Cancer Res. (1999) 5:2638–2645.
   PubMed Web of Science ®Google Scholar
• SUN J, NAM S, LEE CS et al: CEP1612, a dipeptidyl proteasome inhibitor, induces p21WAF1 and p27KIP1 expression and apoptosis and inhibits the growth of human lung adenocarcinoma A-549 in nude mice. Cancer Res. (2001) 61(4):1280–1284.
   PubMed Web of Science ®Google Scholar
• ALBELDA S, WIEWRODT R, D S: Gene therapy for lung neoplasms. Lung Cancer (2002) 23:265–277.
   Google Scholar
• NIETHAMMER AG, XIANG R, JC B: A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat. Med. (2002) 8:1369–1375.
   PubMed Web of Science ®Google Scholar
• SALGIA R, AT S: Molecular abnormalities in lung cancer. J Clin. Oncol. (1998) 16:1207–1217.
   PubMed Web of Science ®Google Scholar
• ANTELMAN D, MACHEMER T, BG H: Inhibition of tumor cell proliferation in vitro and in vivo by exogenous pllORB, the retinoblastoma tumor suppressor protein. Oncogene (1995) 10:697–704.
   PubMed Web of Science ®Google Scholar
• MHASHILKAR AM, SCHROCK RD, HINDI M: Melanoma differentiation associated gene-7 (IVIDA-7): a novel antitumor gene for cancer gene therapy. Mol. Med. (2001) 4:271–282.
   Google Scholar
• SAEKI T, MHASILKAR AM, SWANSON X: Inhibition of human lung cancer growth following adenovirus mediated mda-7 gene expression PI vivo. Oncogene (2002) 21:4558–4566.
   PubMed Web of Science ®Google Scholar
• SOZZI G, TORNIELLI S, TAGLIABUE E: Absence of FHIT protein in primary lung tumors and cell lines with FHIT gene abnormalities. Cancer Res. (1997) 57:5207–5212.
   PubMed Web of Science ®Google Scholar
• TSENG JE, KEMP BL, KHURI FR: Loss of FHIT is frequent in stage I non-small cell lung cancer and in the lungs of chronic smokers. Cancer Res. (1999) 59.
   PubMedGoogle Scholar
• JI L, FANG B, YEN N: Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. Cancer Res. (1999) 59:3333–3339.
   PubMed Web of Science ®Google Scholar
• SUZUKI H, TAKAHASHI T, KUROISHI T et al.: p53 mutations in non-small cell lung cancer in Japan: association between mutations and smoking. Cancer Res. (1992) 52:734–736.
   PubMed Web of Science ®Google Scholar
• ZHANG WW, FANG X, MAZUR W, FRENCH BA, GEORGES RN, ROTH JA: High-efficiency gene transfer and high-level expression of wild type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Tiler. (1994) 1:5–13.
   PubMed Web of Science ®Google Scholar
• ROTH JA, NGUYEN D, LAWRENCE DD: Retrovirus-mediated wild-type p53 transfersto tumors of patients with lung cancer. Nat. Med. (1996) 2:985–989
   PubMed Web of Science ®Google Scholar
• SCHULER M, ROCHLITZ C, HOROWITZ JA et al.: A phase I study of adenovirus mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer. Hum. Gen. Flier. (1998) 9:2075–2082.
   Google Scholar
• •A Phase I trial of adenovirus-mediated p53 gene transfer in patients with advanced NSCLC demonstrated minimal toxicity, successful p53 gene transfer and transient regression of injected tumours.
   Google Scholar
• KUBA S, ADAK S et al.: Phase I trial of adenovirus p53 in bronchoalveolar cell lung carcinoma(BAC) administered by bronchoalveolar lavage. Proc. Am. Soc. Clin. Omni (2000) 19:487a.
   Google Scholar
• NEMUNAITIS J, SWISHER S, TIMMONS T et al.: Adenovirus mediated p-53 gene transfer in sequence with cisplatin to tumors of patients with non-small cell lung cancer. Clin. Oncol. (2000) 18:609–622.
   Web of Science ®Google Scholar
• SCHULER M, HERRMANN R, DE GREVE JL et al.: Adenovirus mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small cell lung cancer:; results of a multicenter phase II study. I GM Oncol. (2001) 19:1750–1758.
   Google Scholar
• •A Phase II study of adenovirus-mediated p53 gene transfer in patients receiving chemotherapy for NSCLC failed to demonstrate a difference in tumour response compared to responses in non-injected lesions.
   Google Scholar
• ZHOU Y, McEARCHERN JA, HOWARD E et al.: Dendritic cells efficiently acquire and present antigen derived from lung cancer cells and induce antigen-specific T-cell responses. Cancer Immunol. Immunother. (2003) 52(7):413–22.
   PubMed Web of Science ®Google Scholar
• NEMUNAITIS J: GVAX (GMCSF gene modified tumor vaccine) in advanced stage non small cell lung cancer. J Control Release (2003) 91(1-2):225–231.
   PubMed Web of Science ®Google Scholar
• NEMUNAITIS J, STERMAN D, JABLONS D et al: Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small cell lung cancer. Natl. Cancer Inst. Feb (2004) 18:326–331.
   Google Scholar
• PALMER M, PARKER J, MODI S et al: Phase I study of BLP25 (MUC1 Peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small cell lung cancer. Clin. Lung Cancer (2001) 3(1):49–57.
   PubMedGoogle Scholar
• GOTOH K, YATABE Y, SUGIURA T: Frequency of MAGE-3 gene expression in HLA-A2 positive patients with non-small cell lung cancer. Lung Cancer (1998) 20:117–125.
   PubMed Web of Science ®Google Scholar
• SMITH A, JUSTIN T, MICHAELI D, WATSON SA: Phase I/II study of G17-DT, an anti-gastrin immunogen, in advanced colorectal cancer. Clin. Cancer Res. (2000) 6:4719–4724.
   PubMed Web of Science ®Google Scholar
• NIKITINA E, CLARK J, VB J: Dendritic cells transduced with full length wild-type p53 generate anti-tumor cytotoxic 628 Expert Op/n. Investig. Drugs (2004) 13(6) T-lymphocytes from peripheral blood of cancer patients. Clin. Cancer Res. (2001) 1:2–4.
   Google Scholar
• TAN Y, XU M, WANG W : IL-2 gene therapy of advanced lung cancer patients. Anticancer Res. (1996) 16:1993–1998.
   PubMed Web of Science ®Google Scholar
• DAVIES AM, GANDARA DR, LARA PN Jr et al.: Antisense oligonucleotides in the treatment of NSCLC. Clin. Lung Cancer (2003) 4:S68–S73.
   PubMedGoogle Scholar
• ADVANI R, PEETHAMBARAM P, LUM BL et al.: A phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma. Cancer (2004) 15:321–326.
   Google Scholar
• KELLY K, CROWLEY JJ, BUNN PA: Role of recombinant interferon-a-2a maintenance in patients with limited stage small cell lung cancer responding to concurrent chemo-radiation: a southwest oncology group study. I Clin. Oncol. (1995) 13:2924–2930.
   PubMed Web of Science ®Google Scholar
• LEBEAU B, DELSALMONIERE P et al.: Alpha interferone as maintenance therapy for small cell lung cancer. Proc. Am. Soc. Clin. Oncol. (1999) 18:475a (Abstract 1832).
   Google Scholar
• PUJOL JL, DAURES JP, RIVIERE A et al: Etoposide plus cisplatinwith or without the combinationof 4'-epidoxorubicin plus cyclophosphamidein treatment of extensive small cell lung cancer: A french federation of cancer institutesmulticenter phase III randomized study. .1. Nati Cancer Inst. (2001) 93:300–308.
   PubMedGoogle Scholar
• GUO N, TEMPLETON NS, AL-BARAZI H et al.: Thrombospondin-1 promotes alpha3beta1 integrin-mediated adhesion and neurite-like outgrowth and inhibits proliferation of small cell lung carcinoma cells. Cancer Res. (2000) 60(2):457–466.
   PubMed Web of Science ®Google Scholar
• GRANT SC, KRIS MG, HOUGHTON AN et al.: Long survival of patients with small cell lung cancer after adjuvant treatment with an anti-idiotype antibody BEC2 plus Bacillus Calmette-Guerin. Clin. Cancer Res. (1999) 5(6):1319–1323.
   PubMed Web of Science ®Google Scholar
• DICKER MN, RAGUPATHI G, LIU NX et al.: Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer. Clin Cancer Res. (1999) 5(10):2773–2779.
   PubMed Web of Science ®Google Scholar
• ABRAMS TJ, LEE LB, MURRAY LJ et al.: SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol. Cancer Ther. (2003) 2(5):471–478.
   PubMed Web of Science ®Google Scholar
• SORIA JC, JOHNSON BE CHEVALIER TL: Imatinib in small cell lung cancer. Lung Cancer (2003) 41:S49–S53.
   PubMed Web of Science ®Google Scholar
• JOHNSON BE, FISHER B, FISHER T et al.: Phase II study of STI 571 (Gleevec) for patients with small cell lung cancer. Proceedings ASCO (2002) 21:Abstract 1171.
   Google Scholar
• YANAGISAWA K, SHYR Y, XU BJ et al.: Proteomic patterns of tumor subsets in non-small cell lung cancer. Lancet (2003) 9:415–416.
   Google Scholar
• HIRSCH FR, VARELLA-GARCIA M, BUNN PA et al.: Epidermal growth factor receptor in Non-small cell lung cancer: correlation between gene copy number and protein expression and impact on prognosis. Oncol. (2003) 21:3798–3807.
   Google Scholar
• BEER DG, KARDIA SL, HUANG CC et al.: Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat. Med. (2002) 8:816–824.
   PubMed Web of Science ®Google Scholar
• MEYERSON M, FRANKLIN WA, KELLEY MJ: Molecular classification and molecular genetics of human lung cancers. Semin Oncol Feb; (2004) 31\(Suppl. 1):4–19.
   Google Scholar
• BASELGA J, PFISTER D, COOPER MR: Phase I studies of anti epidermal growth factor receptor chimeric antibody C225 alone and in combination with Cisplatin. Oncol. (2000) 18(4):904–914. Affiliation Nabil Saba MDt & Fadlo Khuri MD -rAuthor for correspondence Emory University School of Medicine and Winship Cancer Institute, Crawford Long Hospital, 550 Peachtree Street, Glenn Building, Atlanta, GA 30308, USA Tel: +1 404 686 3482; E-mail: [email protected]
   Google Scholar